Fecal transplant therapy approved by FDA
During Wednesday’s FDA meeting, the agency approved the first therapy of its kind to treat bacterial infections based on fecal transplants developed by Switzerland’s Ferring Pharmaceuticals. With Rebyota, a remedy is available to treat infections caused by Clostridium difficile, or C. diff, a superbug capable of causing serious and life-threatening diarrhea. Approximately 15,000 to 30,000 deaths occur each year as a result of the infection in the United States. Although fecal microbiota transplants – classified …